The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Boehringer Ingelheim; Merck; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Novartis
Research Funding - AstraZeneca; Bayer; GlaxoSmithKline; Novartis
Travel, Accommodations, Expenses - Merck; Novartis; Pfizer
Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).
 
Daniel Shao-Weng Tan
No Relationships to Disclose
 
Dong-Wan Kim
No Relationships to Disclose
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
 
Gregory J. Riely
Consulting or Advisory Role - Genentech; Novartis; Novartis; Roche
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Novartis; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Yuhan
 
Juergen Wolf
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
 
Takashi Seto
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Kissei Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
Enriqueta Felip
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; MSD; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis
 
Santiago Ponce Aix
No Relationships to Disclose
 
Maud Jonnaert
Employment - Novartis
Honoraria - Novartis
Research Funding - Novartis
Travel, Accommodations, Expenses - Novartis
 
Chun Pan
Employment - Novartis
 
Sinead Dolan
Employment - Novartis
 
Jordi Barretina
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Susan Elizabeth Moody
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Consulting or Advisory Role - N-of-One
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Johnson & Johnson (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)